A shot of medicine costs 700 thousand. How does the medical insurance bureau respond?

On August 5, a staff member of the Letters and Calls Office of the National Medical Insurance Bureau said in an interview that the price of Nosina sodium injection is set by the pharmaceutical companies themselves, so the price of drugs varies from country to country, except for the raw materials and research and development expenses of drugs. In addition, pharmaceutical companies will also consider the issue of profit. At present, the drug is monopolized in the domestic market and the price has remained high.

The staff said that Nocina sodium injection has been included in the medical insurance negotiation agenda since it was listed in China on 20 19, and the country hopes to negotiate with relevant pharmaceutical companies to reduce the drug price to meet the needs of SMA patients.

Since last year, the state has been negotiating with pharmaceutical companies, and the expert group has studied pricing. The specific pricing is not clear. But the inclusion of medical insurance has not been discussed. Because the drug price can't come down, it has been impossible to enter the medical insurance catalogue.

Extended data

Local governments negotiate with pharmaceutical companies to reduce drug prices;

The reporter learned that in order to increase the accessibility of drugs for rare diseases to patients, local governments have negotiated with pharmaceutical companies to reduce drug prices. For example, following sanofi's offer13 for treating Gaucher's disease last year, on June 2nd this year, the negotiation results of two special drugs for rare diseases announced by official website, Zhejiang Medical Insurance Bureau showed that "sanofi's" Merzan "(for treating Pompeii) and" Fabzan "(for treating Fabray) were both shortlisted for negotiation.

In terms of cost guarantee, Zhejiang Medical Insurance Bureau stipulates that patients with rare diseases should pay their own expenses when they visit designated treatment hospitals, and other expenses should be directly settled by medical insurance agencies and designated treatment hospitals. Drugs for rare diseases are not included in the total medical insurance budget management and the proportion of drugs in designated treatment hospitals.

The current medical insurance system in China is similar to that in Britain. The NHS (National Medical Service) system in Britain makes the welfare of individual patients highly public and commercialized, and individual disease treatment and health problems are relatively independent of income and are not affected by their purchasing power.

Every drug or treatment of NHS must be evaluated by NICE (National Institute of Health and Clinical Optimization). The evaluation takes the results of "cost-benefit" analysis of drugs as the main criterion to measure whether they are included in medical insurance reimbursement, and puts clinical efficacy and economy at the first place in the selection of medical insurance catalogue, so as to maximize patients' interests under the limited budget.

Hangzhou Net-Why does a needle cost 700,000 yuan? Medical Insurance Bureau: The market monopoly has been talking about price reduction.